NGM Biopharmaceuticals Valuation
| NGMDelisted Stock | USD 2.50 0.14 5.30% |
Based on Macroaxis valuation methodology, the firm appears to be overvalued. NGM Biopharmaceuticals secures a last-minute Real Value of $2.38 per share. The latest price of the firm is $2.5. Our model forecasts the value of NGM Biopharmaceuticals from inspecting the firm fundamentals such as return on equity of -0.7, and Operating Margin of (179.78) % as well as reviewing its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that NGM Biopharmaceutica's price fluctuation is very steady at this time. Calculation of the real value of NGM Biopharmaceuticals is based on 3 months time horizon. Increasing NGM Biopharmaceutica's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the NGM stock is determined by what a typical buyer is willing to pay for full or partial control of NGM Biopharmaceuticals. Since NGM Biopharmaceutica is currently traded on the exchange, buyers and sellers on that exchange determine the market value of NGM Stock. However, NGM Biopharmaceutica's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.5 | Real 2.38 | Hype 2.5 | Naive 2.65 |
The intrinsic value of NGM Biopharmaceutica's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence NGM Biopharmaceutica's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of NGM Biopharmaceuticals helps investors to forecast how NGM stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of NGM Biopharmaceutica more accurately as focusing exclusively on NGM Biopharmaceutica's fundamentals will not take into account other important factors: NGM Biopharmaceutica Total Value Analysis
NGM Biopharmaceuticals is now forecasted to have company total value of (36.13 M) with market capitalization of 128.53 M, debt of 5.38 M, and cash on hands of 297.81 M. The negative valuation of NGM Biopharmaceutica may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial commitments of the company both on and off balance sheet. Investors should carefully check all of the NGM Biopharmaceutica fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(36.13 M) | 128.53 M | 5.38 M | 297.81 M |
NGM Biopharmaceutica Investor Information
About 21.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 0.86. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. NGM Biopharmaceuticals recorded a loss per share of 1.73. The entity had not issued any dividends in recent years. Based on the key measurements obtained from NGM Biopharmaceutica's financial statements, NGM Biopharmaceuticals is not in a good financial situation at the moment. It has a very high risk of going through financial straits in December.NGM Biopharmaceutica Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. NGM Biopharmaceutica has an asset utilization ratio of 2.62 percent. This suggests that the Company is making $0.0262 for each dollar of assets. An increasing asset utilization means that NGM Biopharmaceuticals is more efficient with each dollar of assets it utilizes for everyday operations.NGM Biopharmaceutica Ownership Allocation
NGM Biopharmaceuticals maintains a total of 83.46 Million outstanding shares. Over half of NGM Biopharmaceutica's outstanding shares are owned by institutional investors. These institutional investors are typically referred to as corporate investors that shop for positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.NGM Biopharmaceutica Profitability Analysis
The company reported the last year's revenue of 4.42 M. Reported Net Loss for the year was (142.38 M) with loss before taxes, overhead, and interest of (125.73 M).About NGM Biopharmaceutica Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of NGM Biopharmaceuticals. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of NGM Biopharmaceuticals based exclusively on its fundamental and basic technical indicators. By analyzing NGM Biopharmaceutica's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of NGM Biopharmaceutica's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of NGM Biopharmaceutica. We calculate exposure to NGM Biopharmaceutica's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of NGM Biopharmaceutica's related companies.NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. NGM Biopharmaceuticals, Inc. was incorporated in 2007 and is headquartered in South San Francisco, California. Ngm Biopharmaceutica operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 225 people.
NGM Biopharmaceutica Growth Indicators
Investing in growth stocks can be very risky. If the company such as NGM Biopharmaceutica does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 82.5 M |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Other Consideration for investing in NGM Stock
If you are still planning to invest in NGM Biopharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the NGM Biopharmaceutica's history and understand the potential risks before investing.
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Stocks Directory Find actively traded stocks across global markets | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon |